JP2014529629A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014529629A5 JP2014529629A5 JP2014528963A JP2014528963A JP2014529629A5 JP 2014529629 A5 JP2014529629 A5 JP 2014529629A5 JP 2014528963 A JP2014528963 A JP 2014528963A JP 2014528963 A JP2014528963 A JP 2014528963A JP 2014529629 A5 JP2014529629 A5 JP 2014529629A5
- Authority
- JP
- Japan
- Prior art keywords
- chem
- xaa
- lys
- linker
- derivative according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11180265.8 | 2011-09-06 | ||
| EP11180265 | 2011-09-06 | ||
| US201161532323P | 2011-09-08 | 2011-09-08 | |
| US61/532,323 | 2011-09-08 | ||
| PCT/EP2012/067364 WO2013037690A1 (en) | 2011-09-06 | 2012-09-06 | Glp-1 derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014529629A JP2014529629A (ja) | 2014-11-13 |
| JP2014529629A5 true JP2014529629A5 (enExample) | 2015-10-01 |
| JP6126097B2 JP6126097B2 (ja) | 2017-05-10 |
Family
ID=47882647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014528963A Active JP6126097B2 (ja) | 2011-09-06 | 2012-09-06 | Ｇｌｐ−１誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9758560B2 (enExample) |
| EP (1) | EP2753642B8 (enExample) |
| JP (1) | JP6126097B2 (enExample) |
| CN (2) | CN104039822A (enExample) |
| ES (1) | ES2626013T3 (enExample) |
| WO (1) | WO2013037690A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2846823B1 (en) * | 2012-05-08 | 2019-12-04 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| CN104411322B (zh) * | 2012-05-08 | 2017-05-24 | 诺和诺德股份有限公司 | 双酰化glp‑1衍生物 |
| SI3004155T1 (sl) * | 2013-05-28 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Peptidna spojina |
| ES2741507T3 (es) * | 2014-04-07 | 2020-02-11 | Novo Nordisk As | Compuestos de glp-1 acilados doblemente |
| JP2018012644A (ja) * | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
| CA3022535A1 (en) | 2016-04-28 | 2017-11-02 | Novo Nordisk A/S | Semaglutide in cardiovascular conditions |
| JP6995042B2 (ja) | 2016-05-24 | 2022-02-04 | 武田薬品工業株式会社 | ペプチド化合物 |
| CN109248323B (zh) * | 2017-07-14 | 2023-09-08 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
| KR102665710B1 (ko) | 2017-08-24 | 2024-05-14 | 노보 노르디스크 에이/에스 | Glp-1 조성물 및 그 용도 |
| MX2020010505A (es) | 2018-04-05 | 2021-01-15 | Sun Pharmaceutical Ind Ltd | Analogos novedosos de glp-1. |
| CN113214381B (zh) * | 2018-04-19 | 2024-01-19 | 杭州先为达生物科技股份有限公司 | 酰化的glp-1衍生物 |
| EP4085077A4 (en) | 2019-12-31 | 2024-01-17 | Beijing QL Biopharmaceutical Co., Ltd. | Fusion proteins of glp-1 and gdf15 and conjugates thereof |
| HRP20241159T1 (hr) | 2020-02-07 | 2024-12-06 | Gasherbrum Bio, Inc. | Heterociklički agonisti za glp-1 |
| JP7761567B2 (ja) | 2020-02-18 | 2025-10-28 | ノヴォ ノルディスク アー／エス | 医薬製剤 |
| TW202206429A (zh) | 2020-04-29 | 2022-02-16 | 美商迦舒布魯姆生物有限公司 | 雜環ｇｌｐ—１促效劑 |
| CN113292646B (zh) | 2020-05-29 | 2022-05-13 | 东莞云璟生物技术有限公司 | Glp-1/胰高血糖素双重激动剂融合蛋白 |
| JP2023537501A (ja) | 2020-08-06 | 2023-09-01 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| CN114729060B (zh) | 2020-09-30 | 2022-11-25 | 北京质肽生物医药科技有限公司 | 多肽缀合物和使用方法 |
| CN114621339B (zh) * | 2021-12-28 | 2022-09-23 | 北京惠之衡生物科技有限公司 | 一种长效glp-1衍生物 |
| JP2025509281A (ja) | 2022-03-09 | 2025-04-11 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| CN114621340B (zh) * | 2022-03-11 | 2022-09-23 | 北京惠之衡生物科技有限公司 | 一种酰化的长效glp-1衍生物 |
| US20250206757A1 (en) | 2022-03-21 | 2025-06-26 | Gasherbrum Bio, Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
| EP4323413A4 (en) | 2022-03-30 | 2025-10-15 | Beijing Ql Biopharmaceutical Co Ltd | LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF |
| CN114958883B (zh) * | 2022-04-12 | 2023-01-31 | 北京惠之衡生物科技有限公司 | 一种表达glp-1类似物的重组工程菌及其构建方法 |
| US20250250269A1 (en) | 2022-04-14 | 2025-08-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| KR20250110330A (ko) * | 2022-11-21 | 2025-07-18 | 일라이 릴리 앤드 캄파니 | Gip/glp1 이중 효능제의 제조 방법 |
| WO2024158668A1 (en) * | 2023-01-23 | 2024-08-02 | CrossChem Limited | Compounds for use in keratin treatment |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2100671C (en) * | 1991-02-27 | 1999-02-02 | James S. Huston | Serine rich peptide linkers |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US5662907A (en) | 1992-08-07 | 1997-09-02 | Cytel Corporation | Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes |
| JPH08504209A (ja) * | 1992-12-04 | 1996-05-07 | アボツト・ラボラトリーズ | ６位修飾デカペプチドｌｈｒｈ拮抗薬 |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| US5663907A (en) * | 1996-04-25 | 1997-09-02 | Bright Microelectronics, Inc. | Switch driver circuit for providing small sector sizes for negative gate erase flash EEPROMS using a standard twin-well CMOS process |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| WO1999043706A1 (en) * | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Derivatives of glp-1 analogs |
| NZ506839A (en) | 1998-03-09 | 2003-05-30 | Zealand Pharma As | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| IL155812A0 (en) | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
| EP1696962A2 (en) * | 2003-12-18 | 2006-09-06 | Novo Nordisk A/S | Novel glp-1 analogues linked to albumin-like agents |
| US20070135338A1 (en) | 2004-03-31 | 2007-06-14 | Karyn O'neil | Human GLP-1 mimetibodies, compositions, methods and uses |
| EP2256130B1 (en) | 2005-02-02 | 2013-09-25 | Novo Nordisk A/S | Novel insulin derivatives |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| US20110144010A1 (en) | 2007-06-01 | 2011-06-16 | Novo Nordisk A/S | Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier |
| EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| US20100292133A1 (en) | 2007-09-05 | 2010-11-18 | Novo Nordisk A/S | Truncated glp-1 derivaties and their therapeutical use |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| JP6006118B2 (ja) * | 2009-12-16 | 2016-10-12 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アナログ及び誘導体 |
| JP6039569B2 (ja) | 2010-11-09 | 2016-12-07 | ノヴォ ノルディスク アー／エス | 二重アシル化されたｇｌｐ−１誘導体 |
| CN104411322B (zh) | 2012-05-08 | 2017-05-24 | 诺和诺德股份有限公司 | 双酰化glp‑1衍生物 |
| EP2846823B1 (en) | 2012-05-08 | 2019-12-04 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
-
2012
- 2012-09-06 JP JP2014528963A patent/JP6126097B2/ja active Active
- 2012-09-06 US US14/343,152 patent/US9758560B2/en active Active
- 2012-09-06 EP EP12805429.3A patent/EP2753642B8/en active Active
- 2012-09-06 ES ES12805429.3T patent/ES2626013T3/es active Active
- 2012-09-06 CN CN201280054416.0A patent/CN104039822A/zh active Pending
- 2012-09-06 CN CN201710403766.8A patent/CN107266558A/zh active Pending
- 2012-09-06 WO PCT/EP2012/067364 patent/WO2013037690A1/en not_active Ceased
-
2017
- 2017-01-12 US US15/404,808 patent/US10308700B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014529629A5 (enExample) | ||
| JP2013543853A5 (enExample) | ||
| JP2014501712A5 (enExample) | ||
| RU2013148921A (ru) | Дважды ацилированные производные glp-1 | |
| JP2015517478A5 (enExample) | ||
| JP2017514801A5 (enExample) | ||
| JP2015517477A5 (enExample) | ||
| JP2016523243A5 (enExample) | ||
| JP2010538049A5 (enExample) | ||
| JP2017105819A5 (enExample) | ||
| JP2016529253A5 (enExample) | ||
| JP2013517307A5 (enExample) | ||
| JP2014503526A5 (enExample) | ||
| US11167014B2 (en) | Solid glp-1 derivative compositions for oral administration | |
| JP2018506507A5 (enExample) | ||
| JP5969461B2 (ja) | Ｇｌｐ−１受容体作動薬とガストリンとのペプチド複合体及びその使用 | |
| JP2005528337A5 (enExample) | ||
| JP7432361B2 (ja) | ヒトインスリンまたはそのアナログのアシル化誘導体 | |
| JP2019513126A5 (enExample) | ||
| JP2016526012A5 (enExample) | ||
| EP2844269A1 (en) | Transmucosal delivery of engineered polypeptides | |
| JP2010529004A5 (enExample) | ||
| JP2010515677A5 (enExample) | ||
| JP2015517459A5 (enExample) | ||
| RU2015147876A (ru) | Пероральная дозированная форма соединений глюкагоноподобного пептида-1 |